cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)

Phase 2

Verastem, Inc. (VSTM)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

VSTMPhase 2$725M

cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) Phase 2 Est. Readout

cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)• Pancreatic Ductal Adenocarcinoma (PDAC)185

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in Pancreatic Ductal Adenocarcinoma (PDAC)

AVCTFAP-Exd

Phase 1

View Full Landscape

Drug Information

Target Indication

Pancreatic Ductal Adenocarcinoma (PDAC)

Clinical Trial

NCT07644559

Last updated: 10/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VSTM

Verastem, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

avutometinibPhase 3

Low Grade Serous Ovarian Cancer

avutometinib (VS-6766)Phase 2

Low Grade Ovarian Serous Adenocarcinoma

avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelPhase 2

KRAS Activating Mutation

Avutometinib (VS-6766) + Defactinib (VS-6063)Phase 2

Low Grade Serous Ovarian Cancer

VS-7375Phase 2

Pancreatic Ductal Adenocarcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts